These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 12814260)

  • 1. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
    J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for primary CNS lymphoma: the next step.
    Abrey LE; Yahalom J; DeAngelis LM
    J Clin Oncol; 2000 Sep; 18(17):3144-50. PubMed ID: 10963643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
    Hirono S; Iwadate Y; Higuchi Y; Serizawa T; Nagano O; Matsutani T; Saeki N
    J Neurooncol; 2015 Jun; 123(2):237-44. PubMed ID: 25911295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
    Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
    Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
    Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
    Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
    Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy.
    Ekenel M; Iwamoto FM; Ben-Porat LS; Panageas KS; Yahalom J; DeAngelis LM; Abrey LE
    Cancer; 2008 Sep; 113(5):1025-31. PubMed ID: 18618509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse of primary central nervous system lymphoma 13 years after high-dose methotrexate-based polychemotherapy.
    Steinbeck JA; Stuplich M; Blasius E; Pels H; Glas M; Schlegel U; Herrlinger U
    J Clin Neurosci; 2011 Nov; 18(11):1554-5. PubMed ID: 21868233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.
    Kobayashi H; Yamaguchi S; Motegi H; Kaneko S; Endou S; Onimaru R; Terasaka S; Houkin K
    J Chemother; 2019 Feb; 31(1):35-41. PubMed ID: 30773132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
    Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
    Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
    de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
    Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience.
    Iwabuchi M; Shibamoto Y; Sugie C; Ayakawa S; Ogino H; Baba F
    J Radiat Res; 2016 Mar; 57(2):164-8. PubMed ID: 26661856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
    Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
    Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
    J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous intrathecal injection therapy of methotrexate is a therapeutic option in primary CNS lymphoma.
    Otani R; Yamada R; Kushihara Y; Inazuka M; Shinoura N
    J Clin Neurosci; 2019 Nov; 69():26-30. PubMed ID: 31466902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
    Plotkin SR; Betensky RA; Hochberg FH; Grossman SA; Lesser GJ; Nabors LB; Chon B; Batchelor TT
    Clin Cancer Res; 2004 Sep; 10(17):5643-6. PubMed ID: 15355887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.